FDA, compounding and drug shortage list

Drug compounders sue over weight loss drugs’ removal from FDA shortage list
A trade group representing compounding pharmacies has filed a lawsuit against the Food and Drug Administration (FDA) for removing semaglutide, the active ingredient in Ozempic, from its drug
Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight. | Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s weight loss drugs without a fight.
Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
Compounders Sue FDA for Declaring Ozempic, Wegovy Shortage Over
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year after the FDA formally ended the tirzepaptide shortage.
FDA declares end to Wegovy and Ozempic shortage
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
FDA sets deadline to end sales of Ozempic, Wegovy copycats
Compounding pharmacies and telehealth companies selling lower-cost versions of Novo Nordisk's Ozempic and Wegovy will soon have to halt production after the FDA set deadlines to phase out compounded semaglutide.
Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
Copart: A Compounding Machine
Copart's relentless compounding potential and long-term growth prospects make it a valuable investment. Click to find out why ...
MedCity News2d
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...
Acre Raises $4M at $90M Valuation, Unlocking Bitcoin-Native Compounding for BTC Holders
With its Bitcoin-in, Bitcoin-out model, Acre simplifies compounding for BTC holders while empowering decentralized networks ...